EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exposure–Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM

Samira Merali, Haden Bunn, Caroline Sychterz, Manting Chiang, Shilpa Puli, Amy J Sehnert, Bindu Murthy, Joga Gobburu iD

The Journal of Clinical Pharmacology · 2025

DOI: 10.1002/jcph.70072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Samira Merali und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bristol-Myers Squibb, Princeton, NJ, USA. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP3A Inhibitors, Models, Biological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mavacamten, a cardiac myosin inhibitor, is primarily metabolized by the cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4, and coadministration with strong CYP3A4 or CYP2C19 inhibitors was contraindicated in patients with obstructive hypertrophic cardiomyopathy (HCM) in the US Prescribing Information. This study assessed the safety and efficacy of modifying mavacamten posology to accommodate coadministration with strong CYP3A4 and strong/moderate CYP2C19 inhibitors. Simulations of 5000 virtual patients with obstructive HCM with an equal distribution of CYP2C19 metabolizer phenotypes were performed using population pharmacokinetic and exposure–response modeling approaches. A reference posology and variations thereof were simulated to evaluate long‐term (chronic) and short‐term (1‐week) coadministration with CYP3A4 or CYP2C19 inhibitors. Proportions of patients with left ventricular ejection fraction (LVEF)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicCytochrome P-450 CYP2C19 InhibitorsCytochrome P-450 CYP3A InhibitorsModels, BiologicalHumansMaleMiddle AgedCytochrome P-450 CYP2C19FemaleComputer SimulationCytochrome P-450 CYP3AAgedDrug InteractionsAdultDose-Response Relationship, DrugBenzylaminesUracil

Stichwörter der Autor:innen

CYPdose responsedrug–drug interactionsexposure–responsemodelingsimulation

Substanzen

Cytochrome P-450 CYP2C19 InhibitorsCytochrome P-450 CYP3A InhibitorsCytochrome P-450 CYP2C19MYK-461CYP2C19 protein, humanCYP3A4 protein, humanCytochrome P-450 CYP3ABenzylaminesUracil

Autor:innen und Institutionen

  • Bristol-Myers Squibb, Princeton, NJ, USA.
  • Pumas-AI, Inc., Baltimore, MD, USA.

ORCID-Profile: Joga Gobburu

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

Merali, S., Bunn, H., Sychterz, C., Chiang, M., Puli, S., Sehnert, A. J., Murthy, B., & Gobburu, J. (2025). Exposure–Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70072

Vancouver

Merali S, Bunn H, Sychterz C, Chiang M, Puli S, Sehnert AJ, et al. Exposure–Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70072

BibTeX
@article{Merali2025,
  author = {Merali, Samira and Bunn, Haden and Sychterz, Caroline and Chiang, Manting and Puli, Shilpa and Sehnert, Amy J and Murthy, Bindu and Gobburu, Joga},
  title = {Exposure–Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/jcph.70072}
}
Kostenlos starten →